EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Efficacy of novel activated bamboo charcoal in reducing uremic toxins and enhancing kidney function in chronic kidney disease patients: a pilot randomized controlled trial

Kuo-Chin Hung, Mei-Yueh Lee, Shih-Yuan Hung, Chiao-Yin Sun, Chau-Chung Wu, Cheng-Jui Lin

PeerJ · 2025

DOI: 10.7717/peerj.19007 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PeerJ, 2025. Verfasst von Kuo-Chin Hung und 5 weiteren Autor:innen. Beteiligte Einrichtung: Min-Sheng General Hospital, Division of Nephrology, Department of Medicine, Taoyuan City, Taiwan. Hauptthemen laut MEDLINE: Charcoal, Kidney, Probiotics, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Grant from Taiwan National Science Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The role of uremic toxins in the progression of chronic kidney disease (CKD) and novel treatments to mitigate their effects are critical areas of research. This pilot study investigated the efficacy of a novel activated bamboo charcoal and/or probiotics in reducing uremic toxins and improving renal function in CKD patients.

Methods

This prospective, randomized, open, blinded end-point (PROBE) study included patients with stage 3 CKD. Patients were randomly assigned to one of four groups: activated bamboo charcoal (ABC), probiotics, ABC with probiotics, or standard treatment for 3 months.

Results

A total of 46 patients were enrolled (mean age 66.7 ± 11.5 years, 71.7% male). The ABC and ABC with probiotics groups showed a significant reduction in serum levels of the uremic toxins trimethylamine N-oxide (TMAO), p-cresyl sulfate (PCS), indoxyl sulfate (IS), and phenyl sulfate (PS) after 3 months of treatment (all p < 0.05). There was a particularly pronounced decrease in the percentage of IS in both the ABC group (−23.9 ± 28.9% vs . 33.9 ± 63.4%, p = 0.005) and the ABC with probiotics group (−29.3 ± 30.6% vs . 33.9 ± 63.4%, p = 0.009). The eGFR change ratio also significantly improved in the ABC group compared to the control group (4.6 ± 10.2% vs . −8.6 ± 12.5%, p = 0.011). However, the probiotics group did not exhibit a similar reduction in uremic toxins or an improvement in the eGFR.

Conclusion

This study suggested that ABC significantly reduced uremic toxins and might have potential in improving eGFR in CKD stage 3 patients over a 3-month period. These findings suggest a potential protective effect of ABC on kidney function, highlighting the need for further large-scale, long-term randomized controlled trials to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CharcoalKidneyProbioticsRenal Insufficiency, ChronicUremic ToxinsAgedFemaleHumansMaleMiddle AgedIndicanPilot ProjectsProspective StudiesTreatment OutcomeCresolsSulfuric Acid Esters

Stichwörter der Autor:innen

Activated bamboo charcoalChronic kidney diseaseIndoxyl sulphatePhenyl sulfateProbioticsTMAOp-Cresyl sulfate

Substanzen

4-cresol sulfateCharcoalIndicanUremic ToxinsCresolsSulfuric Acid Esters

Autor:innen und Institutionen

  • Min-Sheng General Hospital, Division of Nephrology, Department of Medicine, Taoyuan City, Taiwan.
  • Tajen University, Department of Pharmacy, Pingtung, Taiwan.
  • Department of Internal Medicine, Kaohsiung Medical University Gangshan Hospital, Division of Endocrinology and Metabolism, Kaohsiung, Taiwan.
  • Kaohsiung Medical University Hospital, Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung, Taiwan.
  • E-Da Hospital, I-Shou University, Division of Nephrology, Department of Internal Medicine, Kaohsiung, Taiwan.
  • I-Shou University, School of Medicine, College of Medicine, Kaohsiung, Taiwan.

Förderung

  • Grant from Taiwan National Science Council

Zitieren

APA

Hung, K. C., Lee, M. Y., Hung, S. Y., Sun, C. Y., Wu, C. C., & Lin, C. J. (2025). Efficacy of novel activated bamboo charcoal in reducing uremic toxins and enhancing kidney function in chronic kidney disease patients: a pilot randomized controlled trial. PeerJ. https://doi.org/10.7717/peerj.19007

Vancouver

Hung KC, Lee MY, Hung SY, Sun CY, Wu CC, Lin CJ. Efficacy of novel activated bamboo charcoal in reducing uremic toxins and enhancing kidney function in chronic kidney disease patients: a pilot randomized controlled trial. PeerJ. 2025. doi:10.7717/peerj.19007

BibTeX
@article{Hung2025,
  author = {Hung, Kuo-Chin and Lee, Mei-Yueh and Hung, Shih-Yuan and Sun, Chiao-Yin and Wu, Chau-Chung and Lin, Cheng-Jui},
  title = {Efficacy of novel activated bamboo charcoal in reducing uremic toxins and enhancing kidney function in chronic kidney disease patients: a pilot randomized controlled trial},
  journal = {PeerJ},
  year = {2025},
  doi = {10.7717/peerj.19007}
}
Kostenlos starten →